GPR55 is an orphan G protein-coupled receptor that may be engaged by some lipid ligands such as lysophosphatidylinositol and cannabinoid-type compounds. Very little is known about its expression pattern and physio-pathological relevance, and its pharmacology and signaling are still rather controversial. Here we analyzed the expression and function of GPR55 in cancer cells. Our data show that GPR55 expression in human tumors from different origins correlates with their aggressiveness. Moreover, GPR55 promotes cancer cell proliferation, both in cell cultures and in xenografted mice, through the overactivation of the extracellular signal-regulated kinase cascade. These findings reveal the importance of GPR55 in human cancer, and suggest that it could constitute a new biomarker and therapeutic target in oncology.
G protein-coupled receptors (GPCRs) constitute the largest superfamily of cellular receptors. They control crucial physiological functions and, consequently, their dysfunction contributes to many human diseases. In fact, they are-together with enzymes-the most common target of therapeutic drugs (Dorsam and Gutkind, 2007) . Deorphanizing GPCRs and expanding our knowledge on GPCR-mediated signaling pathways is therefore a pivotal strategy to design new diagnostic and therapeutic tools for human pathologies. It has been recently proposed that the orphan GPCR GPR55 is engaged and activated by lysophosphatidylinositol (LPI) (Oka et al., 2007) . This original observation, made in cells ectopically expressing GPR55, was shortly corroborated by other reports (Lauckner et al., 2008; Henstridge et al., 2009; Kapur et al., 2009; Oka et al., 2009 Oka et al., , 2010 Yin et al., 2009) . Moreover, LPI has been found to activate GPR55 in cells in which the receptor is endogenously expressed (large dorsal root ganglion neurons (Lauckner et al., 2008) , osteoclasts (Whyte et al., 2009 ) and lymphoblastoid cells (Oka et al., 2010) ), supporting the notion that this phospholipid may be an endogenous GPR55 ligand. Nonetheless, all the functions described so far for LPI on GPR55 come from experiments in which LPI was exogenously added to the cultured cells, and therefore evidence for the role of the naturally occurring lipid in more physiological settings is still missing. It has also been shown that several cannabinoid-type compounds modulate this receptor (Ryberg et al., 2007; Lauckner et al., 2008; WaldeckWeiermair et al., 2008; Henstridge et al., 2009 Henstridge et al., , 2010 Kapur et al., 2009; Yin et al., 2009) . However, the inconsistencies among the pharmacological results obtained so far (some compounds being active in some reports and inactive in others, some being agonists in some studies and antagonists in others, and so on) do not entirely clarify whether GPR55 is an actual cannabinoid receptor (Brown and Robin Hiley, 2009; Ross, 2009 ). GPR55 mRNA is highly expressed in the brain, the adrenal glands, parts of the gastrointestinal tract, spleen, tonsils, testes, thymus (Sawzdargo et al., 1999; Ryberg et al., 2007; Oka et al., 2010) , large dorsal root ganglion neurons (Lauckner et al., 2008) , osteoclasts (Whyte et al., 2009) , certain microglial cells (Pietr et al., 2009) , endothelial cells and mesenteric arterial smooth muscle cells (Daly et al., 2010) , but very little is known about the physiological role of the receptor in these or other tissues. To date, GPR55 has been implicated in the control of pain, specifically in the mechanical hyperalgesia induced by inflammatory and neuropathic pain (Staton et al., 2008) , and in the control of bone formation (Whyte et al., 2009) . Its wide distribution throughout the body suggests, however, that GPR55 might be involved in many other biological functions. As some GPCRs have a prominent role in cancer cell biology (Dorsam and Gutkind, 2007) and, more specifically, GPR55 has been shown to couple to G 12/13 and G q proteins (Ryberg et al., 2007; Lauckner et al., 2008; Henstridge et al., 2009) , which drive oncogenic signaling (Dorsam and Gutkind, 2007; Worzfeld et al., 2008) , we sought to analyze the physiopathological relevance of this receptor in the context of cancer.
We first examined by real-time quantitative PCR the expression of GPR55 in 24 different human cancer cell lines and found that most of them contain detectable levels of GPR55 mRNA (Supplementary Table 1) . We next determined GPR55 expression in a series of 38 human breast tumors that had been previously characterized in terms of their clinico-pathological features (Caffarel et al., 2006) . As shown in Figure 1a , higher levels of this receptor were evident in those tumors with worse prognosis, that is, grade III tumors according to Elston-Ellis criteria, which are characterized by poor cell differentiation, little or no tubule formation, and high mitotic counts (Elston and Ellis, 1993) . We also observed an association between elevated GPR55 levels and high proliferative indexes (determined by the percentage of Ki67-positive cells within the tumors) (Figure 1b) . No relation between GPR55 expression and other predictive or prognostic markers (estrogen and progesterone receptors, ErbB2/Her2, p53, tumor size, and presence of metastases) was found (data not shown). To test whether these observations were restricted to breast cancer, we analyzed GPR55 expression in previously published microarray datasets of pancreatic tumors (Buchholz et al., 2005) and glioblastomas 
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C Andradas et al (Freije et al., 2004; Sun et al., 2006) . We observed, as for breast tumors, a link between high GPR55 levels and the more advanced stages of pancreatic ductal adenocarcinoma progression ( Figure 1c ) as well as higher histological grades (III and IV) in glioblastomas ( Figure 1d ). In addition, we found that high GPR55 expression in glioblastomas was associated with decreased patient overall survival ( Figure 1e ). Of interest, a relationship between increased GPR55 expression and higher proliferative rates (defined as higher Ki67 or PCNA mRNA expression) was also observed in glioblastomas ( Figure 1f ). We next aimed at determining whether the link between GPR55 levels and tumor proliferative indexes found in our expression studies was functionally relevant. First, we observed that stable overexpression of 3xHA-GPR55 in HEK293 cells (characterized in Supplementary Figure S1 ) enhanced their proliferative potential. Thus, the amount of viable cells 48 h after seeding, as determined by the colorimetric 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide thiazol blue (MTT) test, was significantly higher in HEK293-GPR55 cells compared with control HEK293 cells (Figure 2a) . We confirmed the enhancement of proliferation upon GPR55 expression by direct counting of cells (Figure 2b We next analyzed the molecular bases underlying the link between GPR55 expression and cell proliferation. Stable overexpression of this receptor in HEK293 cells, which was associated with higher proliferative rates (Figures 2a-c) , led to enhanced levels of phosphorylated (that is, activated) extracellular signal-regulated kinase (ERK) (Figure 3a , left panel). Well-established activators of ERK (the phorbol ester 12-O-tetradecanoylphorbol-13-acetate), epidermal growth factor and fetal bovine serum were used as positive controls (Figure 3a , left panel). In contrast, no changes were observed in basal phospho-Akt levels ( Figure 3a , right panel). Similar observations were made when modulating the expression of endogenous GPR55 in breast cancer cells. Thus, whereas GPR55 silencing decreased ERK activation, ectopic receptor overexpression had the opposite effect ( Figure 3b, left panel) . Again, these effects were not breast cancer-specific as they were reproduced in glioma cells (Figure 3b, right panel) . No significant changes were observed in phospho-Akt levels when GPR55 expression was modulated in breast cancer or glioma cells (data not shown). The involvement of the ERK cascade in GPR55-mediated enhancement of cell proliferation was further tested by two different approaches. First, we observed that GPR55 expression in HEK293 cells increased the mRNA and protein levels of c-Fos (Figure 3c ), a downstream target of ERK directly related to cell proliferation (Hazzalin and Mahadevan, 2002) . Second, we incubated HEK293 cells with two different MEK inhibitors (PD98059 and U0126) and found that GPR55-expressing cells decreased their proliferative potential down to basal levels, whereas that of wild-type HEK293 cells was virtually unaffected (Figure 3d ). Taken together, these results support that GPR55 signals cell proliferation through ERK.
We next examined the proliferative role of GPR55 in vivo. Subcutaneous tumors were generated in nude mice with T98G glioma cells and GPR55 expression was knocked down by injection of a selective siRNA. As shown in Figure 4a , the growth of those tumors was significantly slower than that of the corresponding control siRNA-treated tumors. Of interest, tumors with lower GPR55 levels showed less Ki67-positive (that is, proliferative) cells (Figure 4b ), decreased phospho-ERK levels ( Figure 4c ) and reduced c-Fos expression ( Figures  4d and e) . Given that GPR55 is expressed in endothelial cells (Waldeck-Weiermair et al., 2008) , we analyzed whether this antitumoral effect had an antiangiogenic component. Thus, we analyzed the expression of the vascular endothelial marker CD31 in GPR55-silenced tumors and their corresponding controls by immunofluorescence, and observed no differences (Supplementary Figure S2 ).
Our results show that GPR55 expression in human tumors from different origins correlates with their aggressiveness. It has been previously described that several GPCRs are overexpressed in human cancers, and that this aberrant expression participates in cancer progression (Dorsam and Gutkind, 2007) . For instance, receptors for chemokines or lysophospholipids such as lysophosphatidic acid or sphingosine-1-phosphate contribute to uncontrolled cell proliferation in many types of cancers (Dorsam and Gutkind, 2007) . Although aberrant tumor cell proliferation is sometimes associated with the activated mutations in GPCRs, there is evidence showing that wild-type GPCRs can become tumorigenic when exposed to an excess of locally produced agonists (Dorsam and Gutkind, 2007) . In this sense, it is interesting to point out that a possible endogenous ligand for GPR55, LPI, is increased in plasma and ascites from ovarian cancer patients compared with samples from healthy controls or patients with non-malignant diseases (Xu et al., 2001 ). This observation, together with the overexpression of GPR55 in malignant tumors reported herein, is in line with the general idea that lysophospholipid signaling is altered in cancer. Thus, elevated levels of lysophosphatidic acid and sphingosine-1-phosphate have been found in body fluids from cancer patients, together with increased amounts of their corresponding target GPCRs, enhanced activity of their biosynthetic enzymes and downregulation of phosphatases that degrade them (Murph et al., 2006) . As a further support for the potential parallelism between lysophosphatidic acid, sphingosine-1-phosphate and LPI, it is worth ]-thymidine for 4 h. After this period, precipitation was achieved by 15 min incubation with ice-cold 5% trichloroacetic acid. The non-incorporated thymidine was rinsed twice with chilled 100% ethanol and cells were solubilized and collected in 0.1 N NaOH containing 0.1% sodium dodecyl sulfate. Radioactivity was measured in a scintillation counter. (d, e) GPR55 expression was modulated in cancer cells (EVSA-T in d, T98G in e) and cell viability was determined by the MTT test 24 h after 12 h of serum starvation (upper panels). Knockdown (left panels) was achieved by siRNA. The double-stranded RNA duplexes for human GPR55 (ON-TARGETplus SMART pools) were from Dharmacon-Thermo Scientific (Lafayette, CO, USA). Sequences were 5 0 -GAAUUCCGCAUGAACAUCAUU-3 0 , 5 0 -GAGAAA CAGCUUUAUCGUAUU-3 0 , 5 0 -AAGAACAGGUGGCCCGAUUUU-3 0 and 5 0 -GCUACUACUUUGUCAUCAAUU-3 0 . The nontargeted control siRNA was from Applied Biosystems-Ambion (Austin, TX, USA) and the sequence was 5 0 -UUCUCCGAACGUGUC ACGUtt-3 0 . DharmaFECT 3 (Dharmacon-Thermo Scientific) was used as transfection reagent. For overexpression experiments (right panels), cells were transfected with a 3xHA-human recombinant GPR55 plasmid (Henstridge et al., 2009) or the corresponding empty vector (pcDNA3). Lipofectamine 2000 (Invitrogen) was used as transfection reagent. For both silencing and overexpression approaches, 24 h after transfection cells were trypsinized and seeded for MTT experiments. Lower panels represent the relative GPR55 mRNA levels, as determined by real-time quantitative PCR, after GPR55 silencing or overexpression. Results are expressed as mean ± s.e.m. *Po0.05; **Po0.01 vs HEK293 cells.
C Andradas et al pointing out that GPR55, as other members of the lysophospholipid GPCR families, exerts its actions, at least in part, through G 12/13 and G q proteins (Ryberg et al., 2007; Lauckner et al., 2008; Henstridge et al., 2009) , which signal oncogenic effects (Dorsam and Gutkind, 2007; Worzfeld et al., 2008) . It is therefore tempting to speculate that LPI, through GPR55, would behave similar to their close relatives lysophosphatidic acid and sphingosine-1-phosphate in terms of involvement in cancer biology. A very recent work proposed that LPI induces MCF-7 cell migration in a GPR55-mediated manner (Ford et al., 2010) . It has also been described that cytosolic phospholipase A2 generates mitogenic LPI in Ras-transformed epithelial cells (Falasca and Corda, 1994) and Ras-transformed fibroblasts (Falasca et al., 1998) . To determine whether LPI is Cells were seeded at a density of 10 Â 10 3 /cm 2 and were serum-starved for 12 h before challenge for 10 min with vehicle (DMSO) or different control stimuli known to activate ERK (that is, 100 ng/ml epidermal growth factor (EGF), 10 nM TPA or 10% fetal bovine serum (FBS)). Cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and proteins were transferred onto polyvinylidene fluoride membranes. Blots were incubated with anti-phospho-ERK (Thr202/Tyr204), anti-ERK, anti-phospho-Akt (Ser473), anti-Akt (Cell Signaling Technology, Danvers, MA, USA) and anti-a-tubulin (Tub) (used as loading control, Sigma-Aldrich). GPR55 promotes cancer cell proliferation C Andradas et al generated in HEK293 cells through this pathway, we inhibited cytosolic phospholipase A2 activity with pyrrophenone (Seno et al., 2001) . This compound blocked the increase in cell proliferation induced by GPR55 overexpression (Supplementary Figure 3) , suggesting that LPI and/or other potential GPR55 endogenous ligands are produced by HEK-GPR55 cells.
In summary, our data shed light on two as yet unclear aspects of the GPR55 receptor, that is, its physiopathological role and the signaling pathways coupled to it. More importantly, the findings presented herein reveal not only the possible relevance of GPR55 in human cancer, but also its potential application as a new biomarker and therapeutic target in oncology. GPR55 knockdown reduces tumor growth in vivo. Subcutaneous tumors were induced in 6-week-old athymic male mice (Harlan Interfauna Iberica, Barcelona, Spain) by subcutaneous injection of 10 Â 10 6 T98G glioma cells. Half of the animals (n ¼ 8) were treated with control siRNA and the other half (n ¼ 8) with GPR55 siRNA. siRNA was injected locally when tumors had reached ca 200 mm 3 (designated as day 1) and on day 7, mixed with AteloGene (Koken, Tokyo, Japan), following the manufacturer's instructions. (a) Time course of the volume of control siRNA-treated (open circles) and GPR55 siRNA-treated (closed circles) T98G cell-derived tumors. Tumors were measured daily from day 1 to day 15 with an external caliper, and volume was calculated as (4p/3) Â (width/2) 2 Â (length/2). Images show one representative tumor of each group. Scale bar ¼ 1 cm. Inset, GPR55 mRNA levels in representative control and GPR55-silenced tumors dissected on day 7, determined by RT-PCR. RNA was isolated and retrotranscribed as described in Figure 1 . The primers used for RT-PCR amplification of human GPR55 were sense 5 0 -GTCCCCCTTCCCGTCCCTGTG-3 0 and antisense 5 0 -GCTGGCTGCGATGCTGTAGATGC-3 0 . GAPDH was used as internal control. (b) Ki67-positive cells (green staining) in one representative tumor of each group. Tissue-tek (Sakura Finetek USA, Torrance, CA, USA) embedded tumor sections were fixed with 4% paraformaldehyde and incubated with anti-Ki67 antibody (Neomarkers-Lab Vision, Fremont, CA, USA). The secondary anti-rabbit Alexa Fluor 488 antibody was from Invitrogen. Cell nuclei were stained with Hoescht 33342 (Invitrogen) and are shown in blue. Confocal fluorescence images were acquired using Laser Sharp 2000 software (Bio-Rad, Hercules, CA, USA). Scale bar: 14.5 mm. The graph corresponds to the quantification of Ki67-positive cells per tumor section (n ¼ 3 animals per group, 10 sections per animal). (c, e) Western blot analysis of phospho-ERK (c) and c-Fos (e) in three representative tumors of each experimental group (control and GPR55 siRNA-treated animals). Tumor lysates were subjected to SDS-PAGE, and proteins were transferred onto polyvinylidene fluoride membranes. Blots were incubated with the following antibodies: anti-phospho-ERK (Thr202/Tyr204), anti-ERK (Cell Signaling Technology, Danvers, MA, USA), anti c-Fos (Santa Cruz Biotechnology) and anti-a-tubulin (Sigma-Aldrich). Luminograms were obtained as described in Figure 3 , and the densitometric analysis (shown in the graph) was performed with Quantity One software (Bio-Rad). (d) Analysis of c-Fos expression in the tumors by real-time quantitative PCR. Primers and reference were those described in Figure 3 . *Po0.05; **Po0.01 vs control siRNA-treated tumors.
